Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

X-Linked Retinitis Pigmentosa: early-phase trial registry

A small indexed set (9 trials) with no open enrollment listed right now.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

9 US clinical trials · none currently recruiting · #1,916 of 28,707 conditions by registered trial count

X-Linked Retinitis Pigmentosa: 9 US clinical trials tracked, none currently recruiting.

X-Linked Retinitis Pigmentosa is the subject of 9 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 2 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Janssen Research & Development, running 4 of these trials.

Enrollment posture brief

Registry condition x-linked-retinitis-pigmentosa

OPEN 0 | RECR 0% | LATE 2 | EARLY 6 | RANK #1916 | SPON 4

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%Acute Otitis Media22.2%Acute Heart Failure11.1%X-Linked Retinitis Pigme (th…0%
Open-enrollment share among volume-matched conditions near X-Linked Retinitis Pigmentosa

X-Linked Retinitis Pigmentosa has no open enrollment in this registry pull (9 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for X-Linked Retinitis Pigmentosa on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. X-Linked Retinitis Pigmentosa is recruiting below its size-band peers.

    0 of 9 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates X-Linked Retinitis Pigmentosa research.

    Janssen Research & Development accounts for 4 of 9 trials (44.4%). 4 distinct sponsors appear on at least one study for this condition label.

  3. Most X-Linked Retinitis Pigmentosa trials plan to enrol fewer than 100 people.

    Median target enrolment is 42 among the 9 trials that report a genuine target (sentinel values excluded). 8 of those (88.9%) plan for fewer than 100 participants.

  4. X-Linked Retinitis Pigmentosa research is mostly interventional.

    8 interventional and 1 observational studies make up this index (88.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 23Phase 32

Indexed trials (enrollment closed)

9 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 3 97 participants

Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

Janssen Research & Development

NCT04794101

ACTIVE NOT RECRUITING Phase 2 85 participants

A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP

Beacon Therapeutics

NCT04850118

ACTIVE NOT RECRUITING Phase 1 29 participants

Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations

Beacon Therapeutics

NCT03316560

ACTIVE NOT RECRUITING Phase 2 24 participants

A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)

Janssen Research & Development

NCT06646289

ACTIVE NOT RECRUITING Phase 1 21 participants

4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)

4D Molecular Therapeutics

NCT04517149

ACTIVE NOT RECRUITING Phase 2 14 participants

A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)

Beacon Therapeutics

NCT06333249

COMPLETED Phase 3 105 participants

Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

Janssen Research & Development

NCT04671433

COMPLETED Phase 1 50 participants

A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112

Biogen

NCT03116113

COMPLETED 42 participants

Long-term Follow-up Gene Therapy Study for RPGR- XLRP

Janssen Research & Development

NCT04312672

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 3
Phase 3 2

Top Sponsors

Named interventions

Most-linked intervention names on X-Linked Retinitis Pigmentosa records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

AAV5-hRKp.RPGR Biological
2 trials
rAAV2tYF-GRK1-RPGR Biological
2 trials
BIIB112 Biological
1 trials
Genetic: AAV5-hRKp.RPGR Biological
1 trials
Genetic: AAV5-hRKp.RPGR Low Dose Biological
1 trials
Genetic: AAV5-hRKp.RPGR Intermediate Dose Biological
1 trials
Control Drug
1 trials
rAAV2tYF-GRK1-hRPGRco Biological
1 trials

US sites by state

Facility locations filed on X-Linked Retinitis Pigmentosa trials. A trial with sites in several states counts in each.

Texas 6 trials
Massachusetts 6 trials
Florida 6 trials
Pennsylvania 5 trials
Oregon 5 trials
North Carolina 5 trials
Michigan 5 trials
Ohio 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this X-Linked Retinitis Pigmentosa page

9 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No X-Linked Retinitis Pigmentosa trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Janssen Research & Development sponsors the most X-Linked Retinitis Pigmentosa trials on record, review their full trial history before evaluating a specific study. See Janssen Research & Development's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This X-Linked Retinitis Pigmentosa condition card totals 9 registered trials; most-linked intervention AAV5-hRKp.RPGR; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.